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Human kallikrein-related peptidases (KLKs) are 15 homol-
ogous serine proteases involved in several (patho)physio-
logical processes, including cancer. Secreted as precursors,
they are activated upon proteolytic release of a short pro-
peptide. We searched for interconnection of KLKs within
extracellular proteolytic networks leading to activation of
protease zymogens and found that (i) pro-KLK activation by
other KLKs is scarce, with the exception of pro-KLK11,
which is efficiently activated by KLK4 and 5; (ii) pro-KLK4
is activated by matrix metalloproteinase 3; and (iii) trypsin-
like KLKs efficiently activate the serine protease urokinase.
Our observations provide new insights into the regulation of
these important tumor-associated proteases.
Keywords: cancer; matrix metalloproteinases; proteases;
urokinase; zymogen activation.
Introduction
Proteolysis is one of the essential and widespread post-trans-
lational processes affecting proteins in all living organisms
(Barrett, 2004; Lopez-Otin and Bond, 2008). Proteases not
only degrade other proteins but also positively regulate,
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directly or indirectly, the activity of numerous bioactive mol-
ecules and are consequently involved in an impressive num-
ber of (patho)physiological processes (Lopez-Otin and Bond,
2008). Remarkable examples are provided by human kallik-
rein-related peptidases (KLKs), which recently came into
focus because of their clinical relevance as diagnostic, prog-
nostic and/or predictive tumor biomarkers, and as potential
therapeutic targets (Borgono and Diamandis, 2004).
The KLK superfamily includes 15 serine (Ser-) proteases
(KLK1–15) whereby all genes are located on chromosome
19q13.4 and constitute the largest protease gene cluster in
the human genome (Borgono and Diamandis, 2004). These
25–30 kDa secreted enzymes display a wide expression pat-
tern in tissues and body fluids (Shaw and Diamandis, 2007)
and participate in several physiological processes such as
skin desquamation, tooth development, neuronal plasticity or
semen liquefaction (Borgono and Diamandis, 2004; Pampa-
lakis and Sotiropoulou, 2007). Along with this, some KLKs
are aberrantly expressed in pathologies, including skin, neu-
rodegenerative and/or malignant disorders, e.g., prostate,
breast and ovarian cancer (Borgono and Diamandis, 2004;
Pampalakis and Sotiropoulou, 2007).
KLKs are secreted as zymogens and are extracellularly
activated via proteolytic removal of a rather short N-terminal
propeptide (Borgono and Diamandis, 2004). This process
thus represents a key step in the regulation of their activity.
Upon activation, they display a trypsin- or chymotrypsin-like
enzymatic activity (Borgono and Diamandis, 2004; Debela
et al., 2006b, 2008). As KLKs are devoid of any other
domain besides the protease domain, their function is likely
to rely exclusively on their proteolytic activity towards their
substrates including extracellular matrix proteins, growth
factors and membrane receptors (Borgono and Diamandis,
2004; Debela et al., 2008; Hollenberg et al., 2008; Emami
and Diamandis, 2010). Consequently, KLK activation has
been actively investigated in the past 5 years and is currently
proposed to occur via reaction cascades during which one
given KLK activates another KLK (Borgono and Diamandis,
2004; Pampalakis and Sotiropoulou, 2007; Yoon et al., 2007,
2009; Debela et al., 2008).
In this context, we designed a strategy allowing high-
throughput analysis of putative pro-KLK activators, which
we searched among tumor-related Ser-proteases such as
KLKs themselves, as well as urokinase (uPA) (Dano et al.,
2005). In parallel, we tested KLKs for their capacity to affect
the pro-uPA zymogen. Furthermore, in the particular case of
pro-KLK4, which displays a Gln residue at the P1 position
of its activation cleavage site, whereas KLK zymogens rather
display an Arg or a Lys residue (Borgono and Diamandis,
2004), we challenged pro-KLK4 with some tumor-associated
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matrix metalloproteinases (MMP-2, -3, -9, and, membrane
type 1-/MT1-MMP) (Itoh and Nagase, 2002; Freije et al.,
2003).
Results
Activation and inactivation of pro-KLKs by KLKs
To allow for efficient, high-throughput screening, pro-KLKs
were cloned and expressed in Escherichia coli as chimeric
proteins bearing N- and C-terminal extensions (i.e., a His-
tag and a Tag100 epitope, respectively, Figure 1A). Upon
exposure of pro-KLKs to potential activators, we analyzed
the reaction mixture by immunoblot, considering that acti-
vation would result in a loss of His-tag reactivity, along with
the occurrence of a Tag100-reactive species displaying a
slightly lower molecular weight (Figure 1A). Using this strat-
egy, we were able to investigate 63 pro-KLK/KLK couples.
Overall results are summarized in Table 1, while selected
examples are depicted in Figure 1B.
Pro-KLK activation by other KLKs was limited to pro-
KLK11, which we found to be efficiently processed from an
approximate 27 kDa species, reacting both with the His-tag
and the Tag100 mAb, into an approximate 23 kDa, His-tag
deficient form, by KLK4 and KLK5 (Figure 1B, enzyme
substrate molar ratio 1/10, 5 h exposure), and to a lesser
extent by KLK6 and KLK8 (Figure 1B, note the persistence
of the His-tagged, uncleaved form). Amino-terminal micro-
sequencing indicated that the KLK11 species generated upon
exposure to KLK4 or KLK5, actually bear the Ile-Ile-Lys-
Gly amino-terminus of mature KLK11 and, thus, correspond
to the active form of the protease.
By contrast, (pro-)KLKs appeared remarkably prone to
proteolytic inactivation or degradation (Table 1). For
instance, pro-KLK11 activation, particularly by KLK5, coin-
cides with the occurrence of an approximate 15 kDa,
Tag100-reactive degradation product (Figure 1A and B). As
this species is not observed when pro-KLK11 is exposed to
KLK11 (Figure 1B), it rather results from direct processing
of (pro-)KLK11 by other KLKs, than from KLK11 autode-
gradation. Another relevant example is provided by pro-
KLK13 (approximately 25 kDa). Indeed, whereas the
non-treated zymogen remains stable upon incubation at
378C, it is converted by KLK4 into an approximate 21 kDa,
His-tag-reactive, Tag100-deficient form, indicating, again,
proteolytic inactivation of the enzyme (Figure 1A, B). Final-
ly, upon incubation with KLK5, pro-KLK5 looses both the
His-tag and the Tag100 reactivity, reflecting its extensive
cleavage/degradation (Figure 1A, B), as also confirmed by
silver staining (data not illustrated).
Interplay of KLKs with (pro-)urokinase
In addition to KLKs, uPA is another well-characterized,
tumor-associated, trypsin-like Ser-protease. Indeed, this
enzyme has been known for a long time to contribute to
tumor cell growth and dissemination (Sperl et al., 2001;
Dano et al., 2005). As crosstalk is a common feature for
human proteolytic systems, we investigated the capacity of
uPA to target pro-KLKs, as well as the reciprocal activity of
KLKs to affect pro-uPA.
Upon exposure to uPA, none of the pro-KLKs was found
to be processed (data not shown). In contrast, as previously
reported for KLK2 and KLK4 (Frenette et al., 1997; Takaya-
ma et al., 1997, 2001; Beaufort et al., 2006), all tested KLKs,
with the exception of KLK7 (i.e., the unique chymotrypsin-
like peptidase among the enzymes which we investigated),
converted single chain pro-uPA (approximately 47 kDa) into
two molecular species (Figure 2A, upper panel) that seem
similar to those generated upon exposure to its canonical
activator plasmin: the approximate 29 kDa mature catalytic
domain (B-chain), and the approximate 17 kDa binding
domain (A-chain). Accordingly, proteolytic activity measure-
ment demonstrated that pro-uPA is indeed activated by
KLK4, 5, 6, 8, 10 and 11, whereas KLK7 leaves the zymo-
gen inactive (Figure 2A, lower panel and Figure 2B, for
KLK5, 6 and 7). In some cases, a further degradation of the
uPA A-chain was also observed.
Activation of pro-KLK4 by matrix metalloproteinases
Differing from other KLKs, pro-KLK4 displays a Gln resi-
due at the P1 position of its activation cleavage site (Borgono
and Diamandis, 2004) and is thus rather unlikely to be acti-
vated by trypsin- or chymotrypsin-like enzymes. Apart from
Ser-proteases, several soluble or membrane-associated
MMPs are also expressed in the extracellular microenviron-
ment of malignant tumor cells and contribute to tumori-
genesis and metastatic spread (Itoh and Nagase, 2002; Freije
et al., 2003). Among these proteases, we evaluated the capac-
ity of MMP-2, -3, -9, and MT1-MMP to affect pro-KLK4.
Additionally, a recently reported variant of MMP-9, MMP-9D,
was also investigated (Ries et al., 2007). As illustrated in
Figure 3A, MMP-3 converted recombinant pro-KLK4 into a
slightly lower molecular mass species. This processing,
which was detectable after 4 h exposure to MMP-3 in an
enzyme/substrate molar ratio of 1/10 and increased over
time, actually corresponds to activation of the KLK4 zymo-
gen, as indicated by proteolytic activity measurement (Figure
3B). In contrast, MMP-2, -9, -9D and MT1-MMP, neither
activated nor degraded pro-KLK4 (data not shown).
Discussion
Although their exact (patho)physiological functions remain
to be clarified, KLKs, including the well-known prostate spe-
cific antigen (PSA/KLK3), have recently been the focus of
attention as promising tumor biomarkers (Borgono and Dia-
mandis, 2004). Particularly, identification of the proteolytic
activators of these enzymes, which are currently thought to
comprise Ser-proteases, including KLKs themselves, has
emerged as a challenging task (Borgono and Diamandis,
2004; Pampalakis and Sotiropoulou, 2007). However, anal-
ysis of pro-KLKs activation is rather difficult owing to par-
ticular (pro-)KLK features. For instance, with the exception
of pro-KLK5, all pro-KLKs carry a short pro-domain (i.e.,
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Figure 1 Activation and inactivation/degradation of human pro-KLKs by KLKs.
(A) Recombinant pro-KLKs were generated as chimeric proteins bearing an amino-terminal His-tag and a carboxy-terminal Tag100 epitope.
Such constructs allow efficient discrimination between activation and proteolytic inactivation/degradation of the zymogens. (B) Pro-KLKs
were left untreated as control (NT), or exposed to KLKs in an enzyme/substrate molar ratio of 1:10, for 1 to 5 h at 378C, before the reaction
mixture was analyzed by immunoblotting, using an anti-His-tag mAb (upper panel), and then an anti-Tag100 mAb (lower panel). Portions
of the films corresponding to the location of relevant antigens and representative of at least two independent experiments are depicted. The
position and molecular mass of standard proteins are indicated on the right-hand side.
4–15 amino acids). Removal of the pro-peptide is thus barely
detectable via general protein electrophoresis procedures
(Borgono and Diamandis, 2004). In addition, KLKs are highly
homologous enzymes (Borgono and Diamandis, 2004),
which do not only display similar molecular masses but also
share macromolecular and synthetic substrates, as well as
inhibitors. In several cases, it is therefore difficult to discrim-
inate between an activated KLK and a KLK-type activator.
Furthermore, it should be noted that commercial Abs are not
available for all KLKs and that some display significant reac-
tivity for more than one KLK (unpublished results). Our
strategy, i.e., to analyze the processing of double-tagged pro-
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Figure 2 Activation of human pro-uPA by KLKs.
Pro-uPA was left untreated as a control (NT), exposed to its known
activator plasmin (Pm), or to KLKs, in an enzyme/substrate molar
ratio of 1:10, for 5 h at 378C. The reaction mixture was subsequently
analyzed by protein electrophoresis followed by Coomassie Blue
staining (A, upper panel), and by proteolytic activity measurement,
using the uPA-selective chromogenic substrate Pefachrome uPA (A,
lower panel and B).qq,q and - respectively depict high, moderate
and no hydrolysis of the chromogenic substrate. One out of three
analyses showing similar results is illustrated.
Figure 3 Activation of human pro-KLK4 by MMPs.
Pro-KLK4 was either left untreated as a control (NT) or exposed to
MMP-3 in an enzyme/substrate molar ratio of 1:10, for 1, 4, 6 or
15 h at 378C. (A) The reaction mixture was analyzed by electro-
phoresis followed by silver staining. (B) Pro-KLK4 was left untreat-
ed or exposed to MMP-3 for 15 h at 378C, before KLK4-related
proteolytic activity was assayed using the fluorogenic substrate
I-1120. Results illustrated are representative of two independent
experiments (RFU: relative fluorescence unit).
KLKs, circumvented these technical limits and allowed us to
carry out high-throughput in vitro analysis of 77 pro-KLK/
potential activator couples. The N- and the C-termini of pro-
enzyme forms of trypsin-like proteases are generally pointing
out the core protease molecule (Gomis-Ru¨th et al., 2002).
Thus, addition of tags is unlikely to affect the overall folding
of the recombinant pro-enzyme forms.
In our study, pro-KLK cleavage leading to stable mature
enzymes rarely occurred, as compared to the extensive acti-
vation cascades currently anticipated in the literature (Bor-
gono and Diamandis, 2004; Pampalakis and Sotiropoulou,
2007). Indeed, Yoon et al. recently proposed that, with regard
to 225 possible combinations, the so-called ‘KLK activome’
might consist of not less than 99 pro-KLK/KLK pairs (Yoon
et al., 2007, 2009). Focusing on the (pro-)KLK subset which
we analyzed, Yoon and coworkers described 20 positive
reactions, whereas our procedure only indicated that KLK4,
5, 6 and 8 trigger pro-KLK11 activation. Concerning the
efficacy of this processing, KLK4 and KLK5 appeared more
potent than KLK6 and KLK8, a tendency which is in good
agreement with the observations by Yoon and colleagues.
Regarding the discrepancies, they probably result from sig-
nificant differences between the two approaches. On the one
hand, we acknowledge that a lower sensitivity of our Ab-
based detection system might explain some differences. On
the other hand, Yoon and coworkers generated recombinant
proteins encompassing an N-terminal His-tag, followed by
the pro-KLK peptide and the six amino-terminal residues of
the KLK mature domain, fused to a soluble, protease-resis-
tant, globular carrier protein (i.e., human fibroblast growth
factor). This interesting model, however, omits the presence
of putative protease-sensitive peptide bonds within the cat-
alytic domain of enzymes, as it only monitors cleavage
around the activation site. In fact, in our model, (pro-)KLKs
appeared rather sensitive to proteolytic inactivation/degra-
dation, whereas under similar experimental conditions, the
KLK-activated serine protease domain of uPA was very sta-
ble. In vivo, glycosylation might stabilize (pro-)KLKs. Still,
internal cleavage has been reported in vitro for several
KLKs, either glycosylated or not (Borgono and Diamandis,
2004; Pampalakis and Sotiropoulou, 2007). Moreover, in the
case of KLK2 and KLK3, the occurrence of truncated KLK
species has actually been confirmed in vivo (Rittenhouse et
al., 1998). Thus, we propose that proteolytic attack and inac-
tivation of (pro-)KLKs might be a relevant regulation path-
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Table 2 N-terminus of the analyzed recombinant KLK zymogen forms.
N-terminal tag Pro-peptide N-terminus of the
mature enzyme
pro-KLK4 MRGSHHHHHHGS SCSQx IINGEDC«
pro-KLK5 MRGSHHHHHHGS NNDVSCDHPSNTVPSGSN IINGSDC«
QDLGAGAGEDARSDDSSSRx
pro-KLK6 MRGSHHHHHHGS EEQNKx LVHGGPC«
pro-KLK7 MRGSHHHHHHGS EEAQGDKx IIDGAPC«
pro-KLK8 MRGSHHHHHHGS QEDKx VLGGHEC«
pro-KLK10 MRGSHHHHHHGS ALLPQNDTRx LDPEAYGAPC«
pro-KLK11 MRGSHHHHHHGS GETRx IIKGFEC«
pro-KLK13 MRGSHHHHHHGS QESSKVLNTNGTSGFx LPGGYTC«
pro-KLK15 MRGSHHHHHHGS AQDGDKx LLEGDEC«
All recombinant pro-forms harbor an N-terminal His-tag, followed by a short peptide consisting of
4–37 amino acids. The activation site is indicated by an arrow. All KLK proteases, with the excep-
tion of KLK4 and KLK13, are supposed to be activated by trypsin-like proteases by cleavage after
an arginine or lysine residue. The distance of the N-terminus of mature human KLK proteases to
the first highly conserved cysteine residue generally consists of six amino acids, with the exception
of KLK10 which displays an unusual insertion of three additional amino acids.
way, along with the sensitivity of these proteases to serpin-
or Kazal-type inhibitors, and to divalent ions (Borgono and
Diamandis, 2004; Debela et al., 2006a, 2007).
In contrast to the well-known coagulation cascade that
consists of sequential proteolytic activations, KLKs seem to
be rather integrated within a proteolytic network which
involves a large array of (pro-)proteases, with no clear hier-
archy. To date, and apart from KLKs themselves, these pro-
teases have been shown to include fibrinolytic enzymes (e.g.,
plasmin), coagulation proteases (e.g., thrombin), as well as
the metalloproteases meprin a and b (Borgono and Diaman-
dis, 2004; Becker-Pauly et al., 2007; Pampalakis and Soti-
ropoulou, 2007; Yoon et al., 2007, 2008, 2009; Ohler et al.,
2010). In the case of pro-meprin activation, up to now
KLK4, 5 and 8 have been shown to activate the zymogen
forms of meprin a and/or b (Becker-Pauly et al., 2007; Ohler
et al., 2010). We now report that trypsin-like KLKs are also
potent activators of the urokinase zymogen, whereas they
leave plasminogen inactive (unpublished data). Interestingly,
plasmin as well as some MMPs are in turn able to trigger
activation of some pro-KLKs. Particularly, as previously
demonstrated for MMP-20 (Ryu et al., 2002), in the present
paper, we report that MMP-3 triggers activation of pro-
KLK4. This finding could be of pathophysiological rele-
vance, as elevated levels of both MMP-3 and KLK4 were
found to be associated with prostate cancer progression,
where pro-KLK4 once activated by MMP-3 could influence
growth and proliferation of tumor cells (Jung et al., 1997;
Ramsay et al., 2008). Another metalloprotease, meprin b,
was recently demonstrated to cleave pro-KLK7 two amino
acids upstream its activation cleavage site (Ohler et al.,
2010). Such processing, although leaving the zymogen inac-
tive, actually primes pro-KLK7 toward further activation by
endoproteases, but also, potentially, by exoproteases (Ohler
et al., 2010). In line with this, dipeptidyl peptidase I was
reported to activate pro-KLK4 (Tye et al., 2009).
In conclusion, although it deserves further confirmation in
vivo, crosstalk between major human proteolytic systems
certainly results in a rapid amplification of global proteolytic
activity, as it is observed during, and thought to participate
in, tumor cell migration and dissemination.
Materials and methods
Reagents
Recombinant human pro-uPA, expressed in E. coli, was a kind gift
from A.G. Saunders (Gru¨nenthal, Aachen, Germany), active KLK5
was generously provided by N. Schechter (University of Pennsyl-
vania, Philadelphia, PA, USA). Human plasmin (4.6 U/mg), purified
from plasma, was from Sigma-Aldrich (St. Louis, MO, USA).
Active high-molecular weight (HMW-) uPA (rheothromb) was from
DeltaSelect (Marburg, Germany). proMMP-9, proMMP-2 and the
catalytic domain of MT1-MMP were purchased from Merck Bio-
sciences/Calbiochem (Darmstadt, Germany). proMMP-9D was iso-
lated as described previously (Ries et al., 2007). The catalytic
domain of MMP-3 was kindly provided by H. Nagase (Imperial
College London, London, UK).
Recombinant (pro-)KLK expression, purification
and/or activation
Recombinant active KLKs were expressed, purified and activated
as reported elsewhere (Debela et al., 2006a,b, 2007). KLK4, 6, 7,
8, 10 and 11 are E. coli-expressed proteins, KLK5 was produced in
insect cells.
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For recombinant pro-KLK production, the coding sequence of
each natural pro-KLK (merops.sanger.ac.uk; see also Table 2) was
inserted in frame with the sequences encoding an (His)6-tag and a
Tag100 epitope, respectively, into the bacterial expression vector
pQE-Double-Tag100 (Qiagen, Hilden, Germany). The resulting
fusion gene encodes the individual pro-KLK framed by an N-ter-
minal (His)6-tag and a C-terminal Tag100.
(His)6-tagged pro-KLKs were purified from lysed bacteria (in 6 M
guanidine hydrochloride, 10 mM Tris-HCl, 100 mM NaH2PO4, 8 mM
2-mercaptoethanol, pH 8.0) via affinity chromatography using a Ni-
NTA Superflow resin (Qiagen) under denaturing conditions. There-
fore, proteins were washed and eluted by a pH gradient: starting off
with lysis buffer, the column was washed with 8 M urea, 10 mM
Tris-HCl, 100 mM NaH2PO4, 8 mM 2-mercaptoethanol, pH 8.0, 7.0,
6.3, 5.9, 4.5, and 4.0, respectively. Most of the recombinant bound
pro-KLK was finally eluted with the buffers at pH 4.5 and 4.0. Prior
to refolding, the purified pro-KLKs were incubated overnight at
room temperature in the elution buffer containing 10 mM dithio-
threitol. For refolding, the urea concentration was subsequently
gradually reduced from 8 M to 4 M, 2 M and 1 M by dialysis. The
latter two refolding buffers contained 5 mM reduced glutathione and
0.5 mM oxidized glutathione (GSH/GSSG ratio 10:1). Finally, the
refolding buffer was exchanged with 100 mM NaCl, 50 mM Tris-
HCl, pH 8.0, 0.005% Tween-20, the protein solution cleared by
centrifugation at 12 000 g, and the purified protein stored at -208C.
In addition, using the pQE-30 vector (Qiagen) pro-KLK4 was also
expressed and purified as an amino-terminally His-tagged protein.
Exposure of zymogens to potential activators
Pro-KLKs or pro-uPA, diluted in 100 mM Tris-HCl, 100 mM NaCl,
pH 7.5, were exposed to potential activators, in an enzyme substrate
molar ratio of 1:10. In the case of treatment of pro-KLK4 by MMPs,
5 mM CaCl2 was added to the reaction mixture. Activation of
proMMP-9 and proMMP-2 was performed by exposure to 1 mM 4-
amino-phenylmercuric acetate for 2 h at 378C, and proMMP-9D was
autocatalytically activated by treatment for 1 h at 378C as described
previously (Ries et al., 2007). After incubation of active enzymes
with pro-KLKs or pro-uPA for various time periods at 378C, the
reaction was stopped on ice and samples were prepared for electro-
phoresis or proteolytic activity measurement (see below).
Protein electrophoresis and immunoblotting
Proteins were denatured in the presence of 2% (w/v) sodium dode-
cyl sulfate and 5% (v/v) 2-mercaptoethanol for 5 min at 958C,
followed by SDS-PAGE. Separated proteins were then either Coo-
massie-stained, silver-stained, or transferred onto polyvinylidene
fluoride membranes (Pall, Dreieich, Germany).
For amino-terminal microsequencing, proteins, visualized by
Coomassie Blue staining (0.1% w/v) of the membranes, were
excised and subjected to automated Edman degradation in a pulse
liquid phase sequencer (Procise 492, Applied Biosystems, Foster
City, CA, USA).
For (pro-)KLK immunoblots, membranes were blocked with 5%
(v/v) dried skimmed milk, then probed with an anti-His mAb
(Penta-His, Qiagen, Hilden, Germany; 1 mg/ml). Bound Abs were
thereafter detected by a horseradish peroxidase-conjugated Ab
against mouse Ig (Jackson ImmunoResearch Lab, West Grove, PA,
USA; dilution: 1:10 000) followed by a chemiluminescent reaction
(ECL, Amersham Biosciences, Little Chalfont, UK). After several
washes, membranes were reprobed with an anti-Tag100 mAb
(Qiagen; 0.5 mg/ml).
Proteolytic activity measurement
For uPA activity measurement, samples were placed in a 96-well
plate and adjusted to a 160 ml final volume in a 50 mM Tris-HCl,
150 mM NaCl, pH 8.0 buffer, in the presence of 0.13 mM Pefa-
chrome uPA (Bz-b-Ala-Gly-Arg-paranitroanilide, Loxo GmbH,
Dossenheim, Germany). The release of paranitroanilide at 378C was
then monitored at 405 nm in a spectrophotometer (SLT-Labinstru-
ments, Gro¨dig, Austria) over a 30-min time period and the initial
rate of substrate hydrolysis derived from the data was expressed as
DOD, in mU/min.
For KLK4 activity measurement, a 50 mM Tris-HCl, 100 mM
NaCl, 0.05% Tween, pH 8.0 buffer, containing 20 mM I-1120 (Boc-
Val-Pro-Arg-7-amino-4-methylcoumarin, Bachem, Bubendorf, Swit-
zerland) was used and the release of 7-amino-4-methylcoumarin at
378C was monitored in a spectrofluorimeter (SpectraMax Gemini
EM, Molecular Devices, Sunnyvale, CA, USA) over a 30-min time
period, with excitation and emission wavelength of 355 and 460 nm,
respectively. The initial rate of substrate hydrolysis derived from the
data was then expressed as relative fluorescent unit/s.
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